Last reviewed · How we verify
Influsplit SSW® — Competitive Intelligence Brief
phase 3
Inactivated split-virion influenza vaccine
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Influsplit SSW® (Influsplit SSW®) — GlaxoSmithKline. Influsplit SSW is an inactivated split-virion influenza vaccine that stimulates immune response against seasonal influenza strains.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Influsplit SSW® TARGET | Influsplit SSW® | GlaxoSmithKline | phase 3 | Inactivated split-virion influenza vaccine | ||
| H5N1 vaccine (Arepanrix) | H5N1 vaccine (Arepanrix) | Canadian Immunization Research Network | marketed | inactivated split-virion influenza vaccine with adjuvant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Inactivated split-virion influenza vaccine class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Influsplit SSW® CI watch — RSS
- Influsplit SSW® CI watch — Atom
- Influsplit SSW® CI watch — JSON
- Influsplit SSW® alone — RSS
- Whole Inactivated split-virion influenza vaccine class — RSS
Cite this brief
Drug Landscape (2026). Influsplit SSW® — Competitive Intelligence Brief. https://druglandscape.com/ci/influsplit-ssw. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing